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Aim: The purpose of the present study is to show the application of the IAEA TRS-430 QA
procedures of EclipseTMv7.5 TPS for photon energies. In addition, the trends of the deviations
found in the conducted tests were determined.
Background: In the past, the lack of complete TPS QA procedures led to some serious acci-
dents.  So, QA in the radiotherapy treatment planning process is essential for determination
of  accuracy in the radiotherapy process and avoidance of treatment errors.
Materials and methods: The calculations of TPS and measurements of irradiations of the treat-
ment  device were compared in the study. As a result, the local dose deviation values (ı1:
central beam axis, ı2: penumbra and build up region, ı3: inside ﬁeld, ı4: outside beam edges,
ı50–90: beam fringe, RW50: radiological width) and their conﬁdence limit values (including
systematic and random errors) were obtained.
Results: The conﬁdence limit values of ı4 were detected to increase with expanding ﬁeld size.
The  values of ı1 and ı3 of hard wedge were larger than open ﬁelds. The values of ı2 and ı50–90
of the inhomogeneity effect test were larger, especially than other tests of this study. The
average deviation was showed to increase with the rise of the wedge angle. The values of ı3
and ı4 of lung irradiation were outside tolerance.
Conclusions: The QA of TPS was done and it was found that there were no reservations in its
use  in patient treatment. The trend of the deviations is shown.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
organizations..  Backgroundn recent years, complexity of TPS has increased signiﬁcantly
nd this has led to the requirement for a comprehensive
uality assurance (QA) guidelines. Increased attention has
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been paid to quality assurance of treatment planning systems
by many  researchers,2,3,6 several national and international
1,4,5,7o.com (K. Yaray), alkayafadime@hotmail.com (F. Alkaya),
In the past, the lack of complete TPS QA procedures
led to some serious accidents. So, QA in the radiotherapy
treatment planning process is essential for determination of
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Deﬁnition of different regions in a radiation beam, based on the magnitude of the dose and dose gradient (adapted
from Ref.8).
accuracy in the radiotherapy process and avoidance of treat-
ment errors.1
1.1.  QA  guidelines
A number of task groups1,5,8 over the past several years
have developed guidelines and protocols for systematic
QA of 3D radiotherapy treatment planning systems (TPSs),
including speciﬁc QA aspects of a TPS, such as anatom-
ical description, beam description, dose calculations, and
data output and transfer. Many  studies have been per-
formed to address speciﬁc problems associated with treat-
ment planning and dose calculation procedures.9–12 Some
studies13–16 were related to the performance of a speciﬁc
TPS.
The general requirements of QA of TPS in radiothe-
rapy have already been discussed in the literature.1–3 Some
reports1–4 have been published to help physicists in the imple-
mentation of a comprehensive QA program. Comprehensive
report of IAEA for QA is called TRS-430 report.1
TRS-430 report1 includes four steps of QA program; accep-
tance tests, commissioning, periodic QA program and patient
speciﬁc QA. The acceptance test is applied to verify function-
ality and quantity agreement with the speciﬁcation report
attached by manufacturer. The commissioning consists of
two different processes. One includes dosimetric study to
verify the performance of the dose calculation generated
by the TPS. The others are non-dosimetric veriﬁcations to
verify the functionality of the tools of TPS. Periodic QA pro-
gram is implemented to verify reproducibility of planning in
accordance with that established at commissioning. Patient
speciﬁc QA is performed to verify the treatment process as a
whole.1.2.  Criteria  of  acceptability
AAPM TG 53 report5 and several researchers2,17,18 have deﬁned
different criteria of acceptability of various regions that can
be deﬁned in terms of dose and dose gradient in a photon
beam, as shown in Fig. 1. Venselaar et al.17 has deﬁned a set
of criteria of acceptability based on different tolerances for ı
(local dose deviation) based on the knowledge that dose cal-
culation algorithms provide a better accuracy in the high dose
and small dose gradient region of the beam than in others.
These reports2,5,17 have proposed different tolerances for the
various regions in a photon beam, as given in Table 1.
Deviations between results of calculations and measure-
ments can be expressed as a percentage deviation of the local
dose according to Venselaar et al.17
ı = 100% ×
(
Dcal − Dmeas
Dmeas
)
(1)
where Dcal and Dmeas are calculated dose at particular point
in the phantom and measured dose at the same point in the
phantom, respectively. In low dose regions where the points
were outside the penumbra or under a block, an alternative
comparison was made accordingly to Venselaar et al.17
ı = 100% ×
(
Dcal − Dmeas
Dmeas,cax
)
(2)where Dmeas,cax is dose measured at a point at the same depth
on the central axis of the open beam. If a study consisting
of many  points is evaluated, some statistical assessment can
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Table 1 – The local dose deviations of different dose regions in photon beam.
Local dose deviation Region deﬁnition Dose magnitude and
dose gradient
ı1 © PDDs: for data points on the CAX beyond the depth of dmax © High dose
© Small dose gradient
ı2 © PDDs: for data points in the build-up region
© Proﬁles: for data points in the penumbra, and in regions close to interfaces
of inhomogeneities regions
©  High dose
© Large dose gradient
ı3 © Proﬁles: for data points beyond dmax, within the beam but outside the CAX ©  High dose
© Small dose gradient
ı4 © Proﬁles: for data points off the geometrical beam edges and below
shielding blocks, generally beyond dmax
© Low dose
© Small dose gradient
RW50 © Proﬁles: The radiological width, deﬁned as the width of a proﬁle measured
at half its height compared to the value at the beam axis
–
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(ı50–90 © Proﬁles: The distance between the 5
maximum of the proﬁle) in the penum
e performed on the calculation points and the measurement
oints. Accordingly, conﬁdence limit, , is as follows:
 = |average deviation|  + 1.5 × SD (3)
where SD is the standard deviation.17,18 In Eq. (3), the fac-
or 1.5 is chosen rather arbitrarily, but it was useful for this
urpose in clinical practice.18,19 If a factor greater than 1.5
as used in Eq. (3), this would emphasize the random errors,
hile a factor smaller than 1.5 would increase the relative
mportance of systematic deviations.
The tolerances of ı as deﬁned in Table 4 can be applied
o the conﬁdence limit. At photon beam dose calculation, the
hree different levels of complexity of geometry are given in
able 2.
The evaluation of absolute and relative dose tests was used
n percent difference between the result of TPS MU calculation
nd the result of independent MU calculation. According to
he TRS-430 report,1 criteria of acceptability recommend that
ercent difference must be ≤2% for using no accessories, no
eam modiﬁers and no inhomogeneity. Otherwise, difference
ust be ≤3%.
In case the TPS fails to meet these accuracy requirements,
he NCS report7 suggests the following:(i) Check the basic beam data entered in the TPS and the test
beam data set.
(ii) Adjust the model parameters.
Table 2 – The different levels for complexity of geometry for ph
Geometry 
Phantom 
Simple geometry Homogeneous phantoms 
Complex geometry Non-homogeneous phanto
More complex geometries Non-homogeneous phantod the 90% point (relative to the –
iii) Restrict the clinical use of the TPS to geometries that
passed the test.
(iv) Inform the vendor about the ﬁndings.
1.3.  QA  procedure  in  TPS
A number of authors20–23 have implemented dosimetric and
non-dosimetric tests of QA procedure into TPS with the
guidance of the IAEA TRS 430 report. These authors have
reported that the most critical difference occurred for oblique
incidence, oblique incidence-off axis, shaped ﬁelds and off
axis-wedged.
Some reports24–26 have demonstrated differences of algo-
rithms for various special regions.
2.  Aim
The purpose of the present study is to show the applica-
tion of the IAEA TRS-430 QA procedures of EclipseTMv7.5 TPS
for photon energies by using a dosimetric measurement sys-
tem. As a result of calculations and measurements from test
plans, local dose deviation values were obtained as ı1 (central
beam axis), ı2 (penumbra and build up region), ı3 (inside ﬁeld)
and ı4 (outside beam edges), ı50–90 (beam fringe), RW50 (radio-
logical width) and their conﬁdence limit values (including
systematic and random errors). In addition, the trends of the
deviations found in the conducted tests were determined.
oton beam dose calculation.
Deﬁnition
Beam arrangement
© Rectangular ﬁeld size
© Variation of SSD
© Oblique incidence
ms © Fields with wedge
© Irregular ﬁeld
© Asymmetric collimator settings
© Missing tissue
ms © Combinations of complex geometry
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Table 3 – Details of dosimetric tests performed on TPS in the present study.
Test type Test Test geometry Detail
Energy (MV) Field size (cm × cm)  Depth (cm) Measurement
systems
Note
Photon beam
commissioning
1  Square ﬁelds 6, 18 3 × 3, 5 × 5, 10 × 10, 35 × 35 dmax, 5, 10, 20 WP, PFD3G
2 Rectangular ﬁelds 6, 18 5 × 35, 35 × 5
3 Asymmetric ﬁelds 6, 18 X1 = 2, X2 = 8, Y1 = 3, Y2 = 7,
X1 = 5, X2 = 5, Y1 = 0, Y2 = 10
4 Shaped ﬁelds 6, 18 Cord and corner block convex
and concave aperture
5 Source to surface distance
depence
6,  18 10 × 10 SSD: 90 cm, 100 cm, 110 cm
6 Hard wedge 6, 18 5 × 5, 10 × 10, 20 × 30
(only15 × 30 for 600 W)
15◦, 30◦, 45◦, 60◦ Ws
7 Dynamic wedge 6, 18 5 × 5, 10 × 10, 10 × 20 10 WP, FC23-C, EDR2 15◦, 45◦ EDWs
8 Oblique incidence 6, 18 10 × 10 dmax, 5, 10 WP, PFD3G Gantry angle: 330◦
9 Missing scatter 6, 18 20 × 20 15 SP34, FC23-C
10 Buildup behavior 6, 18 5 × 5, 10 × 10, 20 × 20 0.2 − dmax SP34, PPC05
11 Density correction 6, 18 15 × 10 5.5 SP34-RP, FC23-C, EBT2 With created special phantom
Operational tests
12  Algorithm choice TPS  has single algortihm licence.
So test wasn’t performed
13 Inhomogeneity corrections 6, 18 It was used ﬁelds of Test 27.a a.  Modiﬁed Batho,
b. B. Batho power Law,
c. Equivalent TAR
14 Calculation validity 6, 18 It was used ﬁelds of Test 25.b
15 Calculation grid 6, 18 10 × 10 0 − dmax Calc. grid = 1.25, 2.5, 10 mm
Absolute and
relative dose tests
16 Open ﬁelds 6, 18 5 × 5, 10 × 10, 30 × 30 Isocentre Box technique, different beam
weights
17 Tangential Fields 6, 18 10 × 10, 20 × 20 Tangential  technique, MLC
18 Wedged ﬁelds 6, 18 5 × 5, 10 × 20, 20 × 20 Lateral ﬁelds + AP ﬁeld, different
beam weights
19 MLC shaped ﬁelds 6, 18 It was added MLC to ﬁelds of
Test 16
Box  technique, different beam
weights
20 Inhomogeneity corrections 6, 18 It was used ﬁelds of Test 27.a-b Modiﬁed Batho, same beam
weights
21 Off-axis calculations 6, 18 20 × 20 AP and PA ﬁelds, also 30◦ W
Overall clinical tests
22 Open ﬁeld 6, 18 5 × 5, 10 × 10, 20 × 20 Isocentre SP34, FC65-G Box technique, different beam
weights
23 Blocking ﬁeld 6, 18 It was added MLC to ﬁelds of
Test 22
24 Wedged ﬁeld 6, 18 10 × 10, 20 × 20 15◦, 30◦ Ws and AP- PA ﬁelds
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3.  Materials  and  methods
The commissioning procedure of the IAEA TRS-430 for clinical
photon beams was implemented for pencil-beam convolu-
tion algorithm of EclipseTMv7.5 (Varian Medical Systems, Palo
Alto, CA, USA) TPS that was installed to beam data of Clinac
DHX (2300 CD) linear accelerator (Varian Medical Systems,
Palo Alto, CA, USA). Clinac DHX linear accelerator gener-
ates 6 MV and 18 MV photon energy beams (quality index:
TPR20/10, TPR20/10 = 0.6646 for 6 MV and TPR20/10 = 0.7871 for
18 MV). After the assembly of Clinac DHX linear accelerator,
acceptance tests were implemented and performed to ver-
ify it within recommended speciﬁc tolerance. For beam data
for TPS, measurements were carried out by the RFA-300 3D
radiation ﬁeld analysis system (Wellhöfer Dosimerie GmbH,
Schwarzenbruck, Germany) controlled by OmniPro-Accept
v6.5 software and silicon semiconductor diode detectors
(Wellhöfer Dosimerie GmbH, Schwarzenbruck, Germany).
In this commissioning procedure, results of the calcula-
tion of the plan at the TPS and were compared with those
of the measurement taken from the treatment device in this
study. A TPS calculation grid size of 5 mm was preferred for all
tests because of clinically relevant general use. As a result of
the comparison of test plans, local dose deviation values were
obtained as ı1, ı2, ı3, ı4, ı50–90 and RW50 and conﬁdence limit
values calculated. In addition, the trends of the deviations
found in the conducted tests were determined.
3.1.  Commissioning  of  TPS
The photon beam commissioning tests, operational tests,
absolute and relative dose tests, overall clinical tests are all
detailed in Table 3.
3.1.1.  Machine  capabilities  and  beam  tests
In this process, there are non-dosimetric tests that are
involved in the machine or beam deﬁnition and use. These
tests are performed to check and document the description,
limitations, settings and display etc. of the machine.
3.1.2.  Photon  beam  commissioning  tests
These tests aim to compare the measurement dose and the
calculated dose by TPS. The central axis percentage depth
dose and beam proﬁle measurements were made by using
the RFA-300 3D radiation ﬁeld analysis system controlled
by OmniPro-Accept v6.5 software. The absolute dose mea-
surements were performed with 0.65 cm3 FC65-G, 0.23 cm3
FC23-C farmer type ion chambers and PPC05 parallel plane
chamber connected to DOSE1 electrometer. The ﬁlm dosime-
try measurements were implemented with EBT2, EDR2 ﬁlms
(Gafchromic EBT2, International Speciality Products, Wayne,
NJ; EDR2 ﬁlms, Eastman Kodak120 Company, Rochester, NY)
and a digitizer (VIDAR Dosimetry PRO Advantage, Vidar Sys-
tems Corporation, Hendon, VA).The performance of TPS was investigated the difference
between calculated and measured dose values as a percentage
of the dose measured locally. So, local dose deviation values
were obtained as ı1, ı2, ı3, ı4, ı50–90 and RW50 and conﬁdence
200  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 195–205
Table 4 – According to complexity of geometry, proposed values of the tolerance for percentage deviation of dose at
different local.
Tolerance Simple geometry Complex geometry More complex geometry
ı1 (central beam axis)
High dose, small dose gradient
%  2 % 3 % 4
ı2 (buildup region of central axis and
penumbra region of proﬁles)
High dose, large dose gradient
2  mm or % 10 3 mm or % 15 3 mm or % 15
ı3 (outside central beam axis region)
High dose, small dose gradient
%  3 %  3 %  4
ı4 (outside beam edges) %  3 % 4 % 5
Low dose, small dose gradient
RW50 (radiological width) 2 mm or % 1 
ı50–90 (beam fringe) 2 mm 
limit values calculated. Conﬁdence limit values were evalu-
ated according to Table 4.
3.1.3.  Operational  tests
Operational tests aim to conﬁrm that the function of TPS is
performed whenever a various operational issues related to
dose calculations, such as grid size, algorithm choice, inho-
mogenity correction, etc., are changed.
3.1.4.  Absolute  and  relative  dose  tests
These tests are intended to conﬁrm the accuracy of the basic
monitor unit (MU) calculation method for different ﬁelds,
accessories and media. At this stage, compared are the results
of TPS MU  calculation and the results of independent MU
calculation. Measured beam data of Varian Clinac DHX for
independent MU  calculation are used. According to the TRS-
430 report,1 the criteria of acceptability recommend that a
percent difference must be ≤2% for using no accessories, no
beam modiﬁers and no inhomogeneity. Otherwise, the differ-
ence must be ≤3%.
3.2.  Overall  clinical  tests
Overall clinical tests are aimed to conﬁrm that the abso-
lute dose delivered is in the expected tolerance range after
a speciﬁc clinic plan is prepared through a total planning pro-
cess. The absolute dose measurements were performed with
0.65 cm3 FC65-G connected to DOSE1 electrometer, calibrated
TLD at SP34 solid water phantom (including RW3 material)
and RANDO® Phantom (the Phantom Laboratory, Salem, New
York, USA). All measurements were performed 3 times. Posi-
tion of all measurement points is given in Fig. 2. Conﬁdence
limit values were evaluated according to Table 4.
4.  Results
Although many  conditions of ﬁeld size or measurement depth
in each test are given in Table 3, Table 5 only shows results of
one parameter. These are conﬁdence limit values (calculated
with Eq. (3) with results of all ﬁeld sizes and all measurement
depths in each test.2 mm or % 1 2 mm or % 1
3 mm 3 mm
4.1.  Commissioning  of  TPS
4.1.1.  External  beam  plans:  machine  capabilities  and
beams
At this process, the IAEA TRS 430 checklist was satisfactorily
performed to EclipseTM v7.5 TPS and speciﬁcations deter-
mined by vendor were provided.
4.1.2.  Photon  beam  commissioning
Results of photon beam commissioning were evaluated sepa-
rately with respect to each energy and conﬁdence limits of
individual measurement type (%DD, proﬁle, point dose) in
detail (Table 5).
Results of the square ﬁeld test were found to be satisfac-
tory. These results were within the tolerance limits. Notably, it
was detected that conﬁdence limit values of ı4 increase with
expanding ﬁeld size. The same results were found in the test
of rectangular ﬁelds.
Results of ı1 and ı3 of the hard wedge were larger than
for open ﬁelds. These results were within the tolerance lim-
its. Additionally, it was showed that mean deviations of ı2
for %DD increase with expanding ﬁeld size for each wedge
angle. Remarkably, conﬁdence limit values of ı2 were larger
than open ﬁelds. At the same time, results of the dynamic
wedge were within the tolerance limits. It was detected that
the ı4 values of the hard wedge and dynamic wedge increase
with expanding ﬁeld size and rising wedge angles (Table 5).
At oblique incidence tests, it was found that ı2 conﬁdence
limit values of %DD are outside the tolerances, while the oth-
ers are within tolerances.
According to missing scatter tests, the results were satis-
factory. At investigation of build-up area, it was determined
that values of ı2 decrease with expanding depth and ﬁeld size.
For inhomogeneity effect tests, values of ı3 for low energy
were found outside the tolerances because of high SD (Table 5).
4.1.3.  Operational  tests
Algorithm choice test of operational tests could not be investi-
gated because of the fact that it has a single algorithm licence.
It was observed that TPS used inhomogeneity correction effec-
tively. Furthermore, whenever a parameter relevant to the
dose calculation is changed, dose calculations are set to be
invalid or changing interactively. It was noticed that dose TPS
used calculation grid size, this effect being particularly impor-
tant at large dose gradient area.
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Table 5 – Results of photon beam commissioning performed on TPS.
Test number Test geometry Energy (MV) Number of pointsa Conﬁdence limit
%DD Proﬁle
ı1 (%) ı2 (mm)  ı2 (mm) ı3 (%) ı4 (%) ı50–90(mm)  RW50 (mm)
1 Square ﬁelds 6 SaP 1.00 1.03 1.65 0.90 5.30 [f↑, d↓] 1.78 2.38 [f↑]
18 SaP 0.90 1.20 1.70 1.27 4.96 [f↑, d↓] 1.10 2.89 [f↑]
2 Rectangular ﬁelds 6 SaP 0.79 1.27 1.00 0.97 3.28 [f↑, d↓] 1.53 0.78 [f↑]
18 SaP 1.26 2.25 1.27 1.65 3.73 [f↑, d↓] 0.99 1.63 [f↑]
3 Asymmetric ﬁelds 6 SaP 1.42 1.48 1.37 0.72 3.05 [f↑, d↓] 1.63 1.41 [f↑]
18 SaP 1.17 1.53 1.06 1.90 3.10 [f↑, d↓] 1.72 1.32 [f↑]
4 Shaped ﬁelds 6 SaP 2.07 [b↑] 1.68 1.64 (5.85) 0.71 5.70 [f↑, d↓] 2.36 1.73 [f↑]
18 SaP 2.40 [b↑] 2.54 1.73 (5.25) 1.37 5.51 [f↑, d↓] 1.35 2.56 [f↑]
5 Distance depence 6 SaP 1.40 [ssd↓] 1.68 [ssd↓] 1.47 0.68 3.10 1.41 1.30
18 SaP 1.62 [ssd↓] 1.97 [ssd↓] 1.33 1.39 2.82 1.45 1.25
6 Hard wedge 6 SaP 1.33 2.74 [f↑] 1.36 1.13 4.74 [f↑, d↓, w↑] 1.74 0.65 [f↑]
18 SaP 1.22 3.69 [f↑] 1.30 1.10 4.54 [f↑, d↓, w↑] 1.32 0.91 [f↑]
7 Dynamic wedge 6 SaP – – 2.30 1.90 3.73 [f↑,w↑] 1.90 1.62
18 SaP – – 1.89 1.56 4.1 [f↑,w↑] 2.11 1.92
8 Oblique incidence 6 SaP 0.70 4.00 1.10 0.85 3.66 [d↓] 0.63 0.55
18 SaP 1.00 3.45 0.83 1.06 2.48 [d↓] 1.13 0.30
9 Missing scatter 6 15 – – – 1.17 – – –
18 15 – – – 2.28 – – –
10 Build-up region
(without 0.2 cm)
6  18 – % 0.60–7.40 [d↓] – – – – –
18 27 – % 0.20–53.95 [d↓] – – – – –
11 Inhomogeneity
effect
6  SaP – – 2.62 4.83 3.61 1.75 1.25
18 SaP – – 3.82 2.70 5.11 2.00 1.00
The trends of deviations depending on depth, ﬁeld size, shaped ﬁeld, source to surface distance, wedge angle are denoted by [d↑↓], [f↑↓],  [b↑↓], [ssd↑↓],  [w↑↓], respectively. For example; it has been
denoted that, when the depth is increased, the increasing of dose deviation is showed in the form [d↑], while the reduction of dose deviation is showed in the form [d↓].
The results which are outside the tolerance limits are italicised.
a SaP, scanned all point (measurement precision was accepted 0.1 cm, such as obtained point number is 130 for 1D proﬁle measurement of 10 cm × 10 cm ﬁeld size (%DD and Proﬁle).
202  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 195–205
menFig. 2 – Positions of all measure
4.1.4.  Absolute  and  relative  dose  tests
Test results were evaluated in terms of percent deviation
(mean ± SD) value (Table 6). Many  results of investigation were
found to be satisfactory. But results of the off-axis points test
using asymmetric ﬁelds for all photon energies were without
the tolerance limits (Table 6).
4.2.  Overall  clinical  tests
Clinical tests were performed on homogenous solid phantom
and rando-phantom. Although the results of open ﬁeld, block-
ing ﬁeld tests, were found within the tolerance limits, results
of wedged ﬁeld were outside the tolerance limits, especially for
high energy. Signiﬁcantly, it was showed that average devia-
tions increase with the rise of wedge angle. CT planning for
treatment was adapted to the treatment techniques used in
the clinic (such as the head and neck ﬁve-ﬁeld technique28).
While test results of cranium irradiation were found within
the tolerances, values of ı3 and ı4 of lung irradiation were out-
side the tolerance limits. Reasons for the discrepancy could
include the choice of beam quality or the presence of low den-
sity tissue. For head and neck irradiation, conﬁdence limits
were found in high values because of high SD that is based
on setup error in ﬁve-ﬁeld techniques. The region near the
spinal cord is sensitive to set up errors because of a high doset points at overall clinical tests.
gradient. But the resultant high dose gradient of this technique
is not near to critical organs as the spinal cord.
5.  Discussion
In this study, we commissioned Varian EclipseTMv7.5 TPS in
accordance with the procedure of the IAEA TRS-430 for clinical
photon beams.
The accuracy of the dosimetric calculation of EclipseTM
TPS v7.5.18 has been implemented and reported in detail by
Camargo et al.21 It was reported that the most critical differ-
ence occurs for oblique incidence, oblique incidence off axis,
shaped ﬁelds and off axis wedge. The QA of EclipseTM TPS
v7.3.10 has been reported in detail by Jamema  et al.20 Accord-
ing to that report, it was determined that oblique incidence
calculation does not show a variation outside the tolerance
limits. However, for open and wedged asymmetric ﬁelds, vari-
ation out of the tolerance was found at several points in the
penumbral region.
In this study, it was found that deviations occur for ı2 of
%DD for oblique incidence test, ı2 of %DD for hard wedge, ı2
of proﬁles for dynamic wedge. In addition, the ı4 of proﬁles
(dose outside the ﬁeld) was determined outside the tolerances
for many  tests. Especially, the ı4 of shaped ﬁeld, hard wedge
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 195–205 203
Table 6 – Results of absolute and relative dose tests performed on TPS.
Test number Test geometry Energy Deviation (% (mean ± SD)) Note
1 Open ﬁelds 6 MV 0.16 ± 0.4 5 cm × 5 cm, 10 cm × 10 cm, 30 cm × 30 cm
18 MV −0.08 ± 0.7
2 Tangential ﬁelds 6 MV 0.53 ± 0.1
1.13 ± 0.0
10  cm × 10 cm, 10 cm × 20 cm
10 cm × 20 cm (MLC shielding)
18 MV 0.77 ± 0.3
2.74 ± 0.0
10  cm × 10 cm, 10 cm × 20 cm
10 cm × 20 cm (MLC shielding)
3 Wedge ﬁelds 6 MV −1.06 ± 1.0 5 cm × 5 cm, 10 cm × 20 cm, 20 cm × 20 cm
18 MV 0.16 ± 1.6
4 MLC shielding ﬁelds 6 MV 0.37 ± 0.6 5 cm × 5 cm, 10 cm × 10 cm, 30 cm × 30 cm
18 MV 0.91 ± 0.4
5 Inhomogenity correction 6 MV 0.43 ± 1.3
1.00 ± 1.8
2  ﬁelds, MLC shielding plan
4 ﬁelds, MLC shielding plan
18 MV 0.19 ± 1.0
1.80 ± 2.1
2  ﬁelds, MLC shielding plan
4 ﬁelds, MLC shielding plan
6 Off-axis points 6 MV −0.10 ± 1.3
3.52 ± 0.4
0.12 ± 1
Open  ﬁelds
Asymmetric ﬁelds
Open ﬁelds, 45 wedge ﬁelds
18 MV −0.71 ± 1.4
3.51 ± 0.6
0 ± 0.
Open  ﬁelds
Asymmetric ﬁelds
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The results which are outside the tolerance limits are italicised.
nd dynamic wedge increased with expanding ﬁeld size and
ising wedge angles (Table 5).
At tests of hard and dynamic wedge ﬁelds, the increased
eviation between measurement and calculation can depend
n resultant small errors of basic beam data as wedge proﬁles
nd wedge transmission factors.
Build-up dose tests were observed to show a large differ-
nce for depth from 0.2 cm to dmax. User guideline of Eclipse
uggested to change the grid size of calculation. When the
 mm grid size was changed to the smallest grid size avail-
ble of 1.25 mm,  the variation in the dose calculation in the
uild-up region was reduced. Hence, it was decided that for
atients involving (skin tumors) build-up region dose calcula-
ion, smaller grid size should be used.20
In the study of the TRS 430 report1 used by Murugan et al.22,
he result yields were declared to ﬁnd a max. deviation of
.38% (tolerance: 2%) for all simple tests and 5.94% (toler-
nce: 5%) for complex tests in the presence of inhomogeneity,
eam modiﬁers or beam modiﬁers with asymmetric ﬁeld. In
his study, values of ı2 (penumbra) and ı50–90 (beam fringe) of
nhomogeneity effect test were larger, especially than other
ests.
In the study by Engelsman et al.,24 the differences in beam
ringe and penumbra width increased with increasing beam
nergy. For the Modiﬁed Batho algorithm, the comparison
esults of penumbra values were up to 4.3 mm (penumbra) and
.3 mm (beam fringe) for the low energy beams (≤8 MV), while
hese results were up to 8.5 and 10.0 mm for the high energy
eams (≥15 MV).
In the study by Healy and Murry,25 it was reported that
he EclipseTM analytical anisotropic algorithm (AAA) generally
erform better than the PBC algorithm of EclipseTM, but both
lgorithms did not meet tolerances for asymmetric wedge
elds.
In operational tests of this study, it was found that TPS was
sed effectively in all functions. Results of absolute and rel-
tive dose tests were satisfactory. Only results of the off-axis7 45 wedge ﬁelds
points test asymmetric ﬁelds using for each photon energies
were outside the tolerance limits (Table 6). Jamema  et al.20
reported that results of tests were satisfactory.
According to the study of Gershkevitsh et al.,26 the pilot
study included many  hospitals, different TPSs, a variety of
algorithms of TPS and several beam qualities. The result
yields of the pilot study found a better agreements between
calculations and measurements for more  advanced algo-
rithms (changes in lateral electron and photon transport are
approximately modeled). At the same time, pilot study indi-
cated that larger deviations are observed for higher beam
energies.
At overall clinical tests of this study, average deviations
were showed to increase with a rising wedge angle. In addi-
tion, ı3 and ı4 of lung irradiation were outside the tolerance
(Table 7). Engelsman et al.24 reported that deviations of up
to 3.5% between calculated and measured values of the dose
at the ICRU reference point (ı3) were found. In the report by
Engelsman et al.,24 the PBC algorithm with one-dimensional
corrections, the modiﬁed Batho algorithm and the equivalent
path length algorithm were investigated. In the AAPM Report
85,27 it is recommended to use photon beams of energy of
12 MV or less for non-small-cell lung cancer therapy because
of loss of electron equilibrium within and adjacent to the lung.
Low energy beams should be used for low density tissues. Fol-
lowing this study, lung irradiation of our clinic should use only
6 MV or combinations of 6 and 18 MV.
6.  Conclusion
At commissioning of EclipseTM TPS, it has been observed that
the conducted test is generally within tolerance and is outside
the tolerances in some cases. So, there is no need to follow the
recommendations of the NCS report.7 In addition, the trends
of the deviations found in the conducted tests were deter-
mined. Only the errors found in this study for the parameters
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Table 7 – Results of overall clinical tests performed on TPS.
Test number Test geometry Energy ı3 ı4 Note
Deviation (% (mean ± SD)) Conﬁdence limit Deviation (% (mean ± SD)) Conﬁdence limit
1 Open ﬁeld 6 MV 1.13 ± 0.8 2.33 −1.84 ± 0.4 2.44
18 MV 0.83 ± 1.2 2.63 −1.98 ± 0.5 2.73
2 Blocking ﬁeld 6 MV 0.85 ± 0.4 1.45 −0.77 ± 0.2 1.07 MLC
18 MV 0.57 ± 0.4 1.17 −0.92 ± 0.4 1.52
3 Wedged ﬁeld 6 MV 1.39 ± 0.7
2.04 ± 0.2
2.44
2.34
−3.39  ± 1.6
−3.85 ± 2.7
5.79
7.90
15◦ W
45◦ W
18 MV 1.54 ± 1.1
3.05 ± 0.9
3.19
4.40
−3.94  ± 1.7
−4.81 ± 3.1
6.49
9.46
15◦ W
45◦ W
4 CT planning
for cranium
irradiation
6 MV 1.35 ± 1.6
−0.44 ± 0.8
3.75
1.64
−2.80  ± 0.7
−2.47 ± 0.6
3.85
3.37
a.  Lateral f
b. Lateral + vertex f
5 CT planning
for head and
neck
irradiation
6 MV 1.86 ± 1.8
0.40 ± 6.4
4.56
1000
−2.36  ± 0.5
−6.55 ± 0.4
3.11
7.15
a.  Lateral f.
b. Five F. techniquesa
6 CT planning
for lung
irradiation
18 MV 2.73 ± 2.7
0.67 ± 1.2
6.78
2.47
−7.75  ± 0.4
−7.13 ± 0.6
8.35
8.03
a.  AP, PA f.
b. Box technique
The results which are outside the tolerance limits are italicised.
a Adapted from Ref. 28.
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28. Fogliata A, Cozzi L, Bieri S, Bernier J. Critical appraisal of areports of practical oncology and 
sed in patient treatment planning have to be considered. This
rocedure must be performed entirely after the upgrade of
PS.
This study conﬁrmed the correctness of the beam data
ntered in the TPS during the commissioning. With commis-
ioning tests, it was identiﬁed as a baseline data for an ongoing
A program.
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